4.7 Article

Change in risk of Alzheimer disease over time

Journal

NEUROLOGY
Volume 75, Issue 9, Pages 786-791

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3181f0754f

Keywords

-

Funding

  1. NIH/NIA [AG029652, AG11101, R01AG024871, P30AG10161, R01AG11101, R01AG15819, R01AG021972, U24AG026395, R01AG017917, R01AG009966, U01AG016979]
  2. NIH [R01AG024871, U24AG026395, R01AG017917, R01AG009966, R01NR010211, R01AG030544, RO1AG011101, RC2AG036650, R01AG022018, P30AG010161, R01AG011101, R01HL084209, R01AG032247, R01AG015819, R01AG036042, RC2AG036547, U01AG032984, R01AG024480, P01AG009466, R01AG030142]
  3. Alzheimer's AssociationNIH/ NIEHS [ES10902]
  4. Danone Inc.
  5. Illinois Department of Public Health
  6. Ceregene
  7. Danone Research B.V.
  8. Eisai Inc.
  9. Elan Corporation
  10. Merck Co., Inc.
  11. Pamlab LLC
  12. Orasi Medical, Inc.
  13. Pfizer Inc.
  14. Illinois Department of Public Aid Alzheimer's Disease Assistance Center

Ask authors/readers for more resources

Objective: To assess whether the risk of incidence of Alzheimer disease (AD) varies over time. The increase in numbers of people at the oldest ages in the population will bring an increase in the number of people with AD. Projections of the size of the increase assume the risk of AD is constant. Methods: All persons age 65 or older in a biracial, geographically defined area were invited to participate in a home interview every 3 years. From the approximately 10,000 participants, stratified random samples were selected for detailed clinical evaluation. At each cycle, individuals determined free of AD in a previous cycle, either by examination or by high score on cognitive function tests, were sampled in the subsequent cycle for evaluation for incident AD. The evaluations for disease were structured and uniform across time. These analyses include 1,695 subjects evaluated for incident disease from 1997 through 2008. Results: AD developed in 360 participants. Change over time in risk of incident disease was assessed in logistic regression analyses including evaluation date and controlling for age, gender, education, race, interval from disease-free designation to evaluation for incident disease, and sample design. The time variable (in years) was not significant (odds ratio = 0.970, 95% confidence interval = 0.902 to 1.044). Conclusions: The null relation of evaluation date to disease incidence suggests no recent change in risk of AD over time, and supports this assumption for projections of AD. Neurology (R) 2010;75:786-791

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available